{"value":{"id":1908192,"askingMemberId":5447,"askingMember":null,"house":"Commons","memberHasInterest":false,"dateTabled":"2026-05-20T00:00:00","dateForAnswer":"2026-06-01T00:00:00","uin":"3691","questionText":"To ask the Secretary of State for Health and Social Care, with reference to UIN 114047 on Prescription Drugs: Cost Effectiveness answered on 4 March 2026, if he will provide a copy of the a) impact assessment and b) details of modelling for changes to the National Institute for Health and Care Excellence cost-effectiveness threshold to the Health and Social Care Select Committee.","answeringBodyId":17,"answeringBodyName":"Department of Health and Social Care","isWithdrawn":false,"isNamedDay":false,"groupedQuestions":[],"answerIsHolding":false,"answerIsCorrection":false,"answeringMemberId":4603,"answeringMember":null,"correctingMemberId":null,"correctingMember":null,"dateAnswered":"2026-06-01T00:00:00","answerText":"<p>There are no plans to provide an impact assessment or details of the modelling in relation to changes to the National Institute for Health and Care Excellence’s cost-effectiveness threshold to the Health and Social Care Select Committee. Information included in the impact assessment is commercially sensitive.</p><p>The United Kingdom and United States’ pharmaceutical arrangement is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.</p>","originalAnswerText":"","comparableAnswerText":"","dateAnswerCorrected":null,"dateHoldingAnswer":null,"attachmentCount":0,"heading":"Prescription Drugs: Cost Effectiveness","attachments":[],"groupedQuestionsDates":[]},"links":[{"rel":"self","href":"/Questions/1908192","method":"GET"}]}